Optimus covered stent: Advanced covered stent technology for complex congenital heart disease

Morgan, Gareth J.; Ciuffreda, Matteo; Spadoni, Isabella; DeGiovanni, Joseph V.

doi:10.1111/chd.12596

Cited by 13 publications

(7 citation statements)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early outcomes in our study were satisfactory and comparable with other studies 3,12,17‐19 . During a follow‐up period of 1–12 months, 92% of the patients achieved normalization or good control of the blood pressure.…”

Section: Discussionsupporting

confidence: 87%

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Promphan

Siang

Prachasilchai

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives To assess feasibility and early outcomes of using BeGraft Aortic stent in the treatment of aortic coarctation (CoA). Background BeGraft Aortic stent (Bentley InnoMed, Hechingen, Germany) allows large postdilation diameter up to 30 mm. With availability of lengths of 19–59 mm and lower stent profile, they can be used in native and recurrent CoA in adults and in pediatric patients. Materials and methods This is a multicentre retrospective analysis of 12 implanted BeGraft Aortic stents in CoA between May 2017 and April 2019. Results Twelve patients aged 7.7–38 years (median 18.3 years) with body weight of 19.9–56 kg (median 45.5 kg). Eight patients (66%) had native juxtaductal CoA while four had recurrent CoA after previous surgical or transcatheter treatments. The stents were implanted successfully in all the patients with no serious adverse events. The length of the stents ranged from 27 to 59 mm and the implanted stent diameter varied from 12 to 18 mm. The median intraprocedural CoA pressure gradient decreased from 25 mmHg (range 16–66 mmHg) to 2 mmHg (range 0–13 mmHg). The mean follow‐up duration was 10.2 months. Two patient (16.6%) had residual stent narrowing requiring staged redilation. One patient (8%) had pseudoaneurysm formation at 1 year cardiac CT follow‐up. Conclusions The BeGraft Aortic stent may be considered to be safe and effective in the short term in treatment of CoA from childhood to adulthood. Long‐term follow‐up is needed.

show abstract

Section: Discussionsupporting

confidence: 87%

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Promphan

Siang

Prachasilchai

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…In case of side branch occlusion, previous authors even highlighted the predictable behaviour of the Optimus-CVS covering in response to intentional repermabilisation. 7 Finally, covered stenting for SVASD/PAPVD correction is a newly developed intervention and was mainly performed using 10-ZIG-covered CP stents. 25 The promising characteristics of the Optimus-CVS made this new stent suitable for this procedure, especially since stent length and PTFE-covering design can be customised according to the patient’s needs 11 ( figure 5 ).…”

Section: Discussionmentioning

confidence: 99%

“…to small series. [6][7][8][9][10] Here, we report the largest experience with Optimus stents for the treatment of various congenital cardiovascular defects with a comprehensive focus on indications, stent performance and procedure outcomes.…”

Section: What This Study Addsmentioning

confidence: 99%

Multicentre experience with Optimus balloon-expandable cobalt–chromium stents in congenital heart disease interventions

et al. 2023

View full text Add to dashboard Cite

ObjectivesTo evaluate bare-metal Optimus and polytetrafluoroethylene (PTFE)-covered Optimus-CVS balloon-expandable, cobalt–chromium, hybrid cell–designed stents in congenital heart disease (CHD) interventions.MethodsRetrospective multicentre review of patients with CHD receiving Optimus stents. Stent mechanical behaviour, clinical indications and outcomes were assessed.Results183 stents (49.2% XXL/15-ZIG, 33.3% XL/12-ZIG, 17.5% L/9-ZIG) were implanted (98.9% success rate, 2.3% serious procedural complication rate) in 170 patients (57.6% men, 64.1% adults), median age 23.6 years (IQR, 15.2–39.2) and weight 63.5 kg (IQR, 47–75.7). Indications were right ventricular outflow tract stand-alone stenting or before revalvulation (62.4%), aortic coarctation treatment (15.3%), Fontan-circuit fenestration closure (12.4%) and miscellaneous (10%). 86/170 (50.6%) patients had PTFE-covered stenting (50% prophylactic). In 86/170 (50.6%) patients with stenotic lesions, median percentage of achieved stent expansion was 93.4% (IQR, 85.5%–97.7%), median gradient decreased from 28 mm Hg (IQR, 19–41) to 5 mm Hg (IQR, 1–9) (p<0.001), median vessel diameters increased from 13 mm (IQR, 7.9–17) to 18.9 mm (IQR, 15.2–22) (p<0.001) and percentage of vessel expansion was 45.2% (IQR, 19.8%–91.3%). In 30/36 (83.3%) patients with graft, median dilation of 2 mm (IQR, 2–5) above nominal diameter was achieved. Median stent shortening was 10.9% (IQR, 6.1–15.1) and was associated only with expansion diameter (OR: 0.66, 95% CI: 0.38 to 0.93). No clinically relevant fracture, stent embolisation or dysfunction occurred on a median follow-up of 9 (IQR, 4–14) months.ConclusionsOptimus stents are effective tools for transcatheter treatment of simple and complex CHD. Optimus stents’ reliable mechanical behaviour and particular covering design can promote widespread use.

show abstract

“…As medical technology continues to unfold its potential, new large, balloon-expandable endografts have Covered Stents for Coarctation of the Aorta been released, aiming to have a more favorable profile, increased stability of the covering membrane, and increased radial strength. 6,7 For example, the BeGraft Aortic Stent Graft (Bently Innomed GmbH, Hechingen, Germany) is composed of L605 cobalt-chromium alloy and is available in 3 different stent designs (working diameter of 12-14 mm, 16-18 and 20-24 mm). The 3 designs are based on a series of zigzagging rings with multiple articulations per ring with small modifications at the end rings to accommodate the PTFE tubing.…”

Section: See Article By Morray Et Almentioning

confidence: 99%

Long Arc of Covered Stent Use in Coarctation of the Aorta in the United States

Assenza

Cheatham

Schmidt

2023

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Optimus covered stent: Advanced covered stent technology for complex congenital heart disease

Abstract: Preliminary results show that the Optimus covered stent is safe and efficacious for use in patients with coarctation of challenging morphology. A systemic trial will be required to evaluate this stent for more widespread practice.

Cited by 13 publications

References 8 publications

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Feasibility and early outcomes of aortic coarctation treatments with BeGraft Aortic stent

Multicentre experience with Optimus balloon-expandable cobalt–chromium stents in congenital heart disease interventions

Long Arc of Covered Stent Use in Coarctation of the Aorta in the United States

Contact Info

Product

Resources

About